Compounds > iwr-1 exo
Page last updated: 2024-12-09

iwr-1 exo

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

IWR-1-exo : A dicarboximide having an exo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group. It is a weak axin stabilizer, an analogue of IWR-1-endo. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID1163034
CHEBI ID62883
SCHEMBL ID17369116
MeSH IDM0590294

Synonyms (18)

Synonym
chebi:62883 ,
exo-iwr-1
iwr-1-exo
4-[(3ar,4r,7s,7as)-1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2h-4,7-methanoisoindol-2-yl]-n-(quinolin-8-yl)benzamide
1127442-87-8
SCHEMBL17369116
AKOS024457891
4-[(3ar,4r,7s,7as-rel)-1,3,3a,4,7,7a-hexahydro-1,3-dioxo-4,7-methano-2h-isoindol-2-yl]-n-8-quinolinylbenzamide
exo-iwr 1
iwr 1-exo
J-002832
DTXSID50360787
4-[(1r,2r,6s,7s)-3,5-dioxo-4-azatricyclo[5.2.1.02,6]dec-8-en-4-yl]-n-quinolin-8-ylbenzamide
Q27132253
F81704
rel-4-((3ar,4r,7s,7as)-1,3-dioxo-1,3,3a,4,7,7a-hexahydro-2h-4,7-methanoisoindol-2-yl)-n-(quinolin-8-yl)benzamide
HY-108437
CS-0028662
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
axin stabilizernull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dicarboximideAn imide in which the two acyl substituents on nitrogen are carboacyl groups.
bridged compoundA polycyclic compound in which two rings have two or more atoms in common.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Poly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)IC50 (µMol)0.65150.00190.62935.0000AID1655633; AID748264
Poly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)IC50 (µMol)0.02920.00210.67505.1300AID1655635
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proto-oncogene Wnt-3Homo sapiens (human)EC50 (µMol)5.00000.65002.82505.0000AID425205
Poly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)EC50 (µMol)5.00000.20002.56675.0000AID661307
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
peptidyl-serine phosphorylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
peptidyl-threonine phosphorylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein polyubiquitinationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mitotic spindle organizationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein transportPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mRNA transportPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
spindle assemblyPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cell divisionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomerase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein localization to chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
positive regulation of telomere cappingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of telomeric DNA bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
negative regulation of maintenance of mitotic sister chromatid cohesion, telomericPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cell morphogenesisProto-oncogene Wnt-3Homo sapiens (human)
mesoderm formationProto-oncogene Wnt-3Homo sapiens (human)
gamete generationProto-oncogene Wnt-3Homo sapiens (human)
axon guidanceProto-oncogene Wnt-3Homo sapiens (human)
anterior/posterior axis specificationProto-oncogene Wnt-3Homo sapiens (human)
dorsal/ventral axis specificationProto-oncogene Wnt-3Homo sapiens (human)
gene expressionProto-oncogene Wnt-3Homo sapiens (human)
positive regulation of gene expressionProto-oncogene Wnt-3Homo sapiens (human)
positive regulation of Wnt signaling pathwayProto-oncogene Wnt-3Homo sapiens (human)
neuron differentiationProto-oncogene Wnt-3Homo sapiens (human)
embryonic forelimb morphogenesisProto-oncogene Wnt-3Homo sapiens (human)
embryonic hindlimb morphogenesisProto-oncogene Wnt-3Homo sapiens (human)
canonical Wnt signaling pathway involved in mesenchymal stem cell differentiationProto-oncogene Wnt-3Homo sapiens (human)
positive regulation of osteoblast differentiationProto-oncogene Wnt-3Homo sapiens (human)
positive regulation of collateral sprouting in absence of injuryProto-oncogene Wnt-3Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceProto-oncogene Wnt-3Homo sapiens (human)
regulation of neurogenesisProto-oncogene Wnt-3Homo sapiens (human)
Spemann organizer formation at the anterior end of the primitive streakProto-oncogene Wnt-3Homo sapiens (human)
canonical Wnt signaling pathwayProto-oncogene Wnt-3Homo sapiens (human)
limb bud formationProto-oncogene Wnt-3Homo sapiens (human)
head morphogenesisProto-oncogene Wnt-3Homo sapiens (human)
mammary gland epithelium developmentProto-oncogene Wnt-3Homo sapiens (human)
cellular response to retinoic acidProto-oncogene Wnt-3Homo sapiens (human)
stem cell proliferationProto-oncogene Wnt-3Homo sapiens (human)
midbrain dopaminergic neuron differentiationProto-oncogene Wnt-3Homo sapiens (human)
regulation of mesenchymal stem cell differentiationProto-oncogene Wnt-3Homo sapiens (human)
cell fate commitmentProto-oncogene Wnt-3Homo sapiens (human)
protein polyubiquitinationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of telomere maintenance via telomerasePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein localization to chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein poly-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein auto-ADP-ribosylationPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of canonical Wnt signaling pathwayPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
positive regulation of telomere cappingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
negative regulation of telomere maintenance via telomere lengtheningPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
zinc ion bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
histone bindingPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
frizzled bindingProto-oncogene Wnt-3Homo sapiens (human)
protein bindingProto-oncogene Wnt-3Homo sapiens (human)
protein domain specific bindingProto-oncogene Wnt-3Homo sapiens (human)
receptor ligand activityProto-oncogene Wnt-3Homo sapiens (human)
cytokine activityProto-oncogene Wnt-3Homo sapiens (human)
NAD+ ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
protein bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleotidyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
enzyme bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
metal ion bindingPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
NAD+-protein ADP-ribosyltransferase activityPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
Golgi membranePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
pericentriolar materialPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleoplasmPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
Golgi apparatusPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear bodyPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear membranePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
mitotic spindle polePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nuclear porePoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-1Homo sapiens (human)
extracellular regionProto-oncogene Wnt-3Homo sapiens (human)
extracellular spaceProto-oncogene Wnt-3Homo sapiens (human)
endoplasmic reticulum lumenProto-oncogene Wnt-3Homo sapiens (human)
Golgi lumenProto-oncogene Wnt-3Homo sapiens (human)
plasma membraneProto-oncogene Wnt-3Homo sapiens (human)
endocytic vesicle membraneProto-oncogene Wnt-3Homo sapiens (human)
extracellular matrixProto-oncogene Wnt-3Homo sapiens (human)
extracellular exosomeProto-oncogene Wnt-3Homo sapiens (human)
Wnt signalosomeProto-oncogene Wnt-3Homo sapiens (human)
extracellular spaceProto-oncogene Wnt-3Homo sapiens (human)
Golgi membranePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
pericentriolar materialPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
chromosome, telomeric regionPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nuclear envelopePoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytosolPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
perinuclear region of cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
cytoplasmPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
nucleusPoly [ADP-ribose] polymerase tankyrase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID525194Induction of Axin2 in mouse L cell expressing Wnt and STF assessed as decreased beta-casein level by Western blot method2009Nature chemical biology, Feb, Volume: 5, Issue:2
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.
AID1655635Inhibition of full length human N-terminal GST-tagged TNKS2 ADP-ART catalytic domain (1001 to 1327 residues) using histone H2A as substrate incubated for 20 mins followed by [32P[-NAD+ addition and further incubated for 1 hr by liquid scintillation counte2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.
AID1655632Inhibition of full length human N-terminal His-tagged PARP2 expressed in baculovirus infected Sf9 cells at 200 uM using histone H3.3 as substrate incubated for 20 mins followed by [32P[-NAD+ addition and further incubated for 1 hr by liquid scintillation 2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.
AID748264Inhibition of 6XHis-tagged tankyrase1 (1091 to 1325) (unknown origin) after 60 mins in presence of NAD2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Discovery of novel, induced-pocket binding oxazolidinones as potent, selective, and orally bioavailable tankyrase inhibitors.
AID525450Inhibition of caudal fin regeneration after mechanical resection in zebrafish at 10 uM after 7 days2009Nature chemical biology, Feb, Volume: 5, Issue:2
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.
AID525197Induction of Axin2 stabilization in human DLD1 cells assessed as inhibition of Wnt/beta-casein pathway2009Nature chemical biology, Feb, Volume: 5, Issue:2
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.
AID1655630Inhibition of full length human C-terminal His-tagged PARP1 expressed in baculovirus infected Sf9 cells at 200 uM using chicken core histone as substrate incubated for 20 mins followed by [32P[-NAD+ addition and further incubated for 1 hr by liquid scinti2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.
AID1655633Inhibition of full length human N-terminal GST-tagged TNKS1 ADP-ART catalytic domain (1001 to 1327 residues) using histone H2A as substrate incubated for 20 mins followed by [32P[-NAD+ addition and further incubated for 1 hr by liquid scintillation counte2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.
AID661307Activity of N-terminus hexaHis-tagged human TNSK2 expressed in Escherichia coli BL21 (DE3) cells using biotinylated NAD+ as substrate after 90 mins by Western blot analysis2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Structural basis of selective inhibition of human tankyrases.
AID525451Inhibition of Wnt3A mediated fgf20a expression in Zebrafish resected tail fins after 24 hrs post amputation2009Nature chemical biology, Feb, Volume: 5, Issue:2
Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer.
AID1655641Inhibition of colony formation in human DLD1 cells at 1 uM incubated for 12 days by crystal violet staining based assay2020ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.
AID425205Inhibition of Wnt3 expressed in mouse L-cells assessed as inhibition of Wnt/catanin signaling pathway by luciferase reporter gene assay2009Bioorganic & medicinal chemistry letters, Jul-15, Volume: 19, Issue:14
Structure-activity relationship studies of small-molecule inhibitors of Wnt response.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's2 (40.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pj-34
PJ34 : A member of the class of phenanthridines that is 5,6-dihydrophenanthridine substituted at positions 2 and 6 by (N,N-dimethylglycyl)amino and oxo groups, respectively. It is a potent inhibitor of poly(ADP-ribose) polymerases PARP1 and PARP2 (IC50 of 110 nM and 86 nM, respectively) and exhibits anti-cancer, cardioprotective and neuroprotective properties.		2.2510phenanthridines;
secondary carboxamide;
tertiary amino compound		angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent
N-(6-methyl-1,3-benzothiazol-2-yl)-2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)thio]acetamide
[no description available]		2.0510organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound
iwr-1 endo
IWR-1-endo : A dicarboximide having an endo bridged phthalimide structure, substituted at nitrogen by a 4-(quinolin-8-ylcarbamoyl)benzoyl group.		2.9840benzamides;
bridged compound;
dicarboximide;
quinolines		axin stabilizer;
Wnt signalling inhibitor
xav939
XAV939: selectively inhibits beta-catenin-mediated transcription; structure in first source. XAV939 : A thiopyranopyrimidine in which a 7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine skeleton is substituted at C-4 by a hydroxy group and at C-2 by a para-(trifluoromethyl)phenyl group.		2.0710(trifluoromethyl)benzenes;
thiopyranopyrimidine		tankyrase inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.0510
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0510